Mariko Eguchi
YOU?
Author Swipe
View article: Low microglial activity correlates with hyperactivity in attention deficit/hyperactivity disorder model rats: A study using an adrenergic β2 agonist as a microglia activator
Low microglial activity correlates with hyperactivity in attention deficit/hyperactivity disorder model rats: A study using an adrenergic β2 agonist as a microglia activator Open
View article: Rapid Identification of <i>DUX4::IGH</i> Fusion in Acute Lymphoblastic Leukemia
Rapid Identification of <i>DUX4::IGH</i> Fusion in Acute Lymphoblastic Leukemia Open
Introduction DUX4 is rearranged and overexpressed in a subgroup of acute lymphoblastic leukemia (ALL) with B‐precursor phenotype, with a favorable outcome. Even though characteristic gene expression signature as well as surface expression …
View article: Extensive Affectionate Handling Improves Behaviors, Sociality, Learning, and Memory of Attention Deficit/Hyperactive Disorder Model Rats
Extensive Affectionate Handling Improves Behaviors, Sociality, Learning, and Memory of Attention Deficit/Hyperactive Disorder Model Rats Open
View article: Supplementary Table S12 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S12 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Differentially expressed genes (adjusted P <0.01 ) in STAG2/LMO2 subtype compared to other T-ALL cases.
View article: Data from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Data from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this …
View article: Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Compounds used in single-dose (10uM) drug screening.
View article: Supplementary Table S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Detected mutations by whole genome or RNA sequencing.
View article: Supplementary Table S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Cox proportional hazards regression analysis of EFS and OS.
View article: Supplementary Table S14 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S14 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Up-regulated pathways in STAG2/LMO2 subtype compared to other T-ALL cases for mouse leukemia initiating cells (LIC) signatures analyzed by gene-set enrichment analysis (GSEA).
View article: Supplementary Table S24 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S24 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Lists of T-ALL related genes for filtering tumor-only and RNAseq samples.
View article: Supplementary Table S13 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S13 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Up-regulated pathways in STAG2/LMO2 subtype compared to other T-ALL cases analyzed by gene-set enrichment analysis (GSEA).
View article: Supplementary Table S11 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S11 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Patient characteristics of 24 cases of STAG2/LMO2 subtype T-ALL that were performed genomic analysis.
View article: Supplementary Table S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Differentially expressed genes (adjusted P <0.05) in three TLX3 subtypes (TLX3 γδ, TLX3 immature, TLX3 DP-like) compared to other T-ALL cases.
View article: Supplementary Table S7 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S7 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Detected structural variants by whole genome sequencing.
View article: Supplementary Table S25 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S25 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
CRISPR editing construct sequences.
View article: Supplementary Figure S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The genomic feature of LMO2 γδ-like T-ALL.
View article: Supplementary Table S8 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S8 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Lists of feature genes for expression analysis.
View article: Supplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The gene expression profiles of γδ T-ALL.
View article: Supplementary Figure S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Exploration of targets in STAG2/LMO2 T-ALL.
View article: Supplementary Table S22 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S22 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The results of dose-response validation for 138 compounds.
View article: Supplementary Table S9 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S9 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Differentially expressed genes (adjusted P <0.01 ) of LMO2 γδ-like subtype vs other T-ALL.
View article: Supplementary Figure S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S6 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The feature gene expression of STAG2/LMO2 subtype T-ALL.
View article: Supplementary Figure S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
The clinical features of γδ T-ALL.
View article: Supplementary Table S18 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S18 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Common differentially expressed genes (adjusted P <0.01 ) in PF382-STAG2KO v. PF382-WT model and primary samples with STAG2/LMO2 v. other subtypes.
View article: Supplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Differentially expressed genes (adjusted P <0.01 ) between PF382-STAG2KO and PF382-WT.
View article: Supplementary Figure S9 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S9 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Coverage of ATAC seq, H3K27ac ChIP seq, and RNAseq at the LIN28B and ID1 locus.
View article: Supplementary Table S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
A multi-national consortium of γδ T-ALL study.
View article: Supplementary Table S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Table S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Comparison of clinical characteristics and outcomes between gamma delta T-ALL and non-gamma delta T-ALL.
View article: Supplementary Methods from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Methods from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Supplementary Methods, Supplementary Results, Supplementary Data Figures 1 and 2
View article: Supplementary Figure S7 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Supplementary Figure S7 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk Open
Models for examining the effects of STAG2 inactivation.